重叠适应性子体积处方降低T4鼻咽癌颞叶损伤风险:前瞻性队列研究
本研究针对T4鼻咽癌且PTV与颞叶计划风险体积重叠≥0.1 cm3的患者,比较重叠适应性子体积处方(MD)与标准处方(SD)的长期安全性和疗效。
要点
- 两组5年局部无复发生存和总生存无显著差异。
核心结论
- 重叠适应性子体积处方策略(PTVsv2处方66 Gy)显著降低影像学RTLI发生率,同时保持长期肿瘤控制。
- 症状性RTLI的降低为数值性但未达统计学显著性,需进一步验证。
研究设计与样本
- 非随机、单中心、前瞻性观察性队列研究,采用同期对照(ClinicalTrials.gov NCT03539250)。
- 纳入2018至2022年治疗的T4N0-3M0鼻咽癌患者,PTV与颞叶计划风险体积重叠≥0.1 cm3。
- MD组104例,SD组257例,共361例。
主要发现
- 无局限于PTVsv2的边缘复发。
关键数值与推荐
- MD方法将原发肿瘤PTV(PTVnx)分为非重叠子体积(PTVsv1,处方70 Gy)和重叠子体积(PTVsv2,处方66 Gy),采用同步整合加量。
- SD方法对整个PTVnx处方均匀70 Gy。
临床怎么用
- 对于PTV与颞叶计划风险体积重叠≥0.1 cm3的T4鼻咽癌患者,可考虑采用重叠适应性子体积处方策略以降低RTLI风险。
- 该策略在保持肿瘤控制的同时,降低了颞叶高剂量受照体积。
局限性
- 非随机研究设计,存在选择偏倚可能。
- 症状性RTLI的降低未达统计学显著性,需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Radiation-induced temporal lobe injury (RTLI) remains a major late toxicity in T4 nasopharyngeal carcinoma (NPC) because primary target volumes frequently overlap the temporal lobe planning risk volume, limiting near-maximum dose constraints. This study evaluated the long-term safety and efficacy of an overlap-adapted subvolume prescription strategy. METHODS AND MATERIALS: This nonrandomized, single-institution, prospective observational cohort study with a contemporaneous comparator (ClinicalTrials.gov identifier: NCT03539250) enrolled patients with T4N0-3M0 NPC treated between 2018 and 2022 who had planning target volume (PTV)-temporal lobe planning risk volume overlap ≥0.1 cm3. The modified delineation and planning (MD) approach subdivided the primary tumor PTV (PTVnx) into a nonoverlap subvolume (PTVsv1, prescribed 70 Gy) and an overlapping subvolume (PTVsv2, prescribed 66 Gy) using simultaneous integrated boost. The standard delineation and planning (SD) approach prescribed a uniform 70 Gy to the entire PTVnx. RESULTS: Among 361 patients (MD, n = 104; standard delineation and planning, n = 257), the 5-year cumulative incidence of RTLI was significantly lower in the MD group (23.2% vs 36.2%; P = .019). Multivariable analysis revealed that MD was independently associated with reduced RTLI risk (hazard ratio, 0.56; 95% CI, 0.34-0.94; P = .029). No significant differences were found in 5-year local relapse-free survival (92.3% vs 89.6%; P = .577) or overall survival (84.7% vs 84.4%; P = .896). No marginal recurrences were confined to PTVsv2. After lobe-level propensity-score matching (205 lobes per group), MD achieved significantly lower temporal-lobe maximum dose and dose to 1 cm3 (both P < .001) without differences in volumes receiving 40 to 60 Gy and a borderline reduction in volume receiving ≥65 Gy (P = .053). CONCLUSIONS: An overlap-adapted subvolume prescription strategy (66 Gy to PTVsv2) significantly reduced the incidence of radiographic RTLI while preserving long-term tumor control in anatomically constrained T4 NPC. The reduction in symptomatic RTLI was numerical but did not reach statistical significance and warrants further validation.
引用
- Liao H, Wang J, Lai Y, et al. Overlap-Adapted Subvolume Prescription to Reduce Temporal Lobe Injury Risk in T4 Nasopharyngeal Carcinoma: A Prospective Cohort Study With a Contemporaneous Comparator. Pract Radiat Oncol. 2026. PMID: 42628876. doi:10.1016/j.prro.2026.07.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。